All In Biotech

Drug Trial Radar · NCT06639997

Safety and Tolerability of AZD5148 in Japanese Participants

A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Japanese Adults

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Oct 31, 2024

Primary completion

Dec 25, 2025

Study completion Dec 25, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure safety, tolerability and PK of a single dose of AZD5148 administered via IV bolus or IM injection in healthy Japanese participants.

Conditions

  • Clostridioides Difficile Infection

Interventions

  • AZD5148Drug

    Participants will receive AZD5148 as IM injection or IV bolus

  • PlaceboDrug

    Participants will receive matching doses of placebo as an IM injection or IV bolus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Japanese participants with adverse events (AEs).Time frame: From Randomization (Day -1 or Day 1) to Day 91
  2. Number of participants with serious adverse events (SAEs)Time frame: From Screening (Day -28 to Day -2) to final Follow-up Visit (Day 361)
  3. Number of participants with adverse events of special interest (AESIs)Time frame: From Randomization (Day -1 or Day 1) to final Follow-up Visit (Day 361)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Sumida-ku, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.